These results highlight potential efficacy of drugs targeting PI3K, AKT, MEK, ERK, EGFR, and PDGFRA, as well as APP, ESR1, SMARCA2, HDAC9, AURKC, and NAMPT in selected gliomas. Here, EGFR is linked to central nervous system cancer.